LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 203

Search options

  1. Book: Human immunodeficiency virus type 1 (HIV-1) and breastfeeding

    Kourtis, Athena P. / Bulterys, Marc

    science, research advances, and policy

    (Advances in experimental medicine and biology ; 743)

    2012  

    Author's details Athena P. Kourtis ; Marc Bulterys ed
    Series title Advances in experimental medicine and biology ; 743
    Collection
    Language English
    Size XVII, 315 S. : Ill., graph. Darst., Kt.
    Publisher Springer
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT017207336
    ISBN 978-1-4614-2250-1 ; 9781461422518 ; 1-4614-2250-7 ; 1461422515
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book: Perinatal HIV infection

    Kourtis, Athena P. / Bulterys, Marc

    (Clinics in perinatology ; 37,4)

    2010  

    Author's details guest ed. Athena P. Kourtis ; Marc Bulterys
    Series title Clinics in perinatology ; 37,4
    Collection
    Language English
    Size XXI S., S. 699 - 938 : Ill., graph. Darst.
    Publisher Saunders an imprint of Elsevier
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book
    HBZ-ID HT016648954
    ISBN 978-1-4377-2480-6 ; 1-4377-2480-9
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Article ; Online: Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.

    Henderson, Alexis C / Cholli, Preetam / Lampe, Margaret A / Kourtis, Athena P

    Expert review of anti-infective therapy

    2024  Volume 22, Issue 4, Page(s) 153–167

    Abstract: Introduction: The HIV/AIDS epidemic has been one of the greatest challenges in global health, significantly affecting women of reproductive potential. Considerable advances in antiretroviral therapy for women living with HIV have contributed to ... ...

    Abstract Introduction: The HIV/AIDS epidemic has been one of the greatest challenges in global health, significantly affecting women of reproductive potential. Considerable advances in antiretroviral therapy for women living with HIV have contributed to improvements in quality of life, better reproductive and birth outcomes, and a reduced risk of perinatal transmission.
    Areas covered: Despite the progress made, persistent challenges in access and adherence to antiretroviral drugs may limit their benefits for some women. More pharmacokinetic and safety studies in pregnant and lactating women are urgently needed, as are prospective surveillance systems to evaluate associations between fetal and infant antiretroviral exposures, drug-drug interactions, and pregnancy outcomes.
    Expert opinion: Multipurpose technologies, such as combined HIV and other STI or unintended pregnancy prevention, and innovative delivery methods, such as the development of long-acting antiretrovirals, have the potential to reduce adherence challenges and enhance quality of life for women with HIV. Parallel advances in drug safety testing and surveillance are needed to ensure the health and safety of women with or at risk for HIV and children at risk for perinatal transmission.
    MeSH term(s) Pregnancy ; Infant ; Child ; Female ; Humans ; Anti-HIV Agents/adverse effects ; Pregnancy Complications, Infectious/drug therapy ; Pharmaceutical Preparations ; Lactation ; Infectious Disease Transmission, Vertical/prevention & control ; Prospective Studies ; Quality of Life ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Infections/prevention & control
    Chemical Substances Anti-HIV Agents ; Pharmaceutical Preparations
    Language English
    Publishing date 2024-03-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1080/14787210.2024.2334054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: U.S. Black Women and Human Immunodeficiency Virus Preexposure Prophylaxis Implementation.

    Hoover, Karen W / Kourtis, Athena P / Smith, Dawn K

    Obstetrics and gynecology

    2022  Volume 140, Issue 1, Page(s) 106–109

    Abstract: Black women are disproportionately affected by the U.S. human immunodeficiency virus (HIV) epidemic. Preexposure prophylaxis (PrEP) is a safe and effective intervention for HIV prevention. Increased PrEP implementation is a pillar of the U.S. Department ... ...

    Abstract Black women are disproportionately affected by the U.S. human immunodeficiency virus (HIV) epidemic. Preexposure prophylaxis (PrEP) is a safe and effective intervention for HIV prevention. Increased PrEP implementation is a pillar of the U.S. Department of Health and Human Services' Ending the HIV Epidemic in the U.S. initiative. However, PrEP has been used by a smaller proportion of women with PrEP indications compared with men. The goals of the Ending the HIV Epidemic in the U.S. initiative can be achieved only by increasing PrEP use among Black women. Obstetricians and gynecologists are uniquely poised to provide PrEP services for women. We describe the need for community-to-clinic models to overcome the barriers to PrEP use by Black women and a roadmap for clinician and community organization collaboration to increase access to and use of PrEP by Black women.
    MeSH term(s) Anti-HIV Agents/therapeutic use ; Blacks ; Epidemics ; Female ; HIV ; HIV Infections/epidemiology ; Humans ; Male ; Pre-Exposure Prophylaxis
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2022-06-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000004829
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Prevented perinatal HIV infections in the era of antiretroviral prophylaxis and treatment, United States, 1994-2020.

    Lampe, Margaret A / Nesheim, Steven R / Mendoza, Maria C B / Borkowf, Craig B / Henderson, Alexis C / Ewing, Alexander C / Kourtis, Athena P

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

    2024  

    Abstract: Objective: The primary aim of this serial cross-sectional analysis is to estimate the total number of prevented perinatal HIV transmissions from the time of the initial recommendation for perinatal zidovudine (ZDV) prophylaxis in 1994 through 2020 in ... ...

    Abstract Objective: The primary aim of this serial cross-sectional analysis is to estimate the total number of prevented perinatal HIV transmissions from the time of the initial recommendation for perinatal zidovudine (ZDV) prophylaxis in 1994 through 2020 in the US.
    Methods: The estimated number of prevented transmissions was calculated as annual differences between expected and observed numbers of perinatal HIV transmissions. Annual expected number of transmissions was estimated by multiplying the annual number of births to women with HIV by 0.2255 (22.55%), i.e., the transmission rate of the control group in the ACTG Protocol 076 trial. We used published point estimates or, if only ranges were given, the midpoints of those ranges as the best estimates of the annual numbers of births to women with HIV and infants with perinatal HIV. When data were not available, we linearly interpolated or extrapolated the available data to obtain estimated numbers for each year.
    Results: Between 1978 and 2020, the approximate number of live births to women with HIV was 191 267 (95% confidence interval [CI] 190 392-192 110) and for infants with diagnosed perinatal HIV, it was 21 379 (95% CI 21 088-21 695). Since 1994, the annual number of infants born with HIV decreased from 1263 (95% CI 1194-1333) to 33 in 2019 (95% CI 22-45) and 36 in 2020 (95% CI 25-48), corresponding to a 97% reduction. Cumulatively, an estimated total of 22 732 (95% CI 21 340-24 462) perinatal HIV infections were prevented from 1994 through to 2020.
    Conclusion: The elimination of perinatal HIV transmission-accompanied by the cumulative number of prevented cases exceeding that of perinatal HIV infections-is a major public health achievement in the US.
    Language English
    Publishing date 2024-02-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80149-5
    ISSN 1879-3479 ; 0020-7292
    ISSN (online) 1879-3479
    ISSN 0020-7292
    DOI 10.1002/ijgo.15438
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study.

    Kourtis, Athena P / Zhu, Weiming / Lampe, Margaret A / Huang, Ya-Lin A / Hoover, Karen W

    The lancet. HIV

    2023  Volume 10, Issue 9, Page(s) e588–e596

    Abstract: Background: A study from Botswana identified an increased risk of neural tube defects (NTDs) in infants of mothers with HIV who were treated with dolutegravir around the time of conception. We aimed to examine associations of dolutegravir use with NTDs ... ...

    Abstract Background: A study from Botswana identified an increased risk of neural tube defects (NTDs) in infants of mothers with HIV who were treated with dolutegravir around the time of conception. We aimed to examine associations of dolutegravir use with NTDs and pregnancy loss using large health-care claims databases from the USA, a country with folic acid fortification of food.
    Methods: In this cohort study, we analysed health-care claims data, recorded in the Merative MarketScan commercial database (MarketScan data) and Centers for Medicare & Medicaid Services Medicaid database (Medicaid data) from Jan 1, 2008, to Dec 31, 2020. We identified pregnancies with enrolment during their entire duration among women aged 15-49 years and we estimated time of conception. For each pregnancy, we determined HIV status and periconceptional exposure to dolutegravir or other antiretroviral agents. We estimated and compared the incidence rate of NTDs, stillbirths, and pregnancy loss (ie, spontaneous or induced abortions) by type of periconceptional antiretroviral exposure. We calculated adjusted risk ratios of the adverse outcomes using Poisson models adjusting for demographic and clinical factors.
    Findings: Of 4 489 315 pregnancies in MarketScan data and 14 405 861 pregnancies in Medicaid data that had full enrolment, we identified 69 pregnancies in MarketScan data and 993 pregnancies in Medicaid data that were associated with HIV and periconceptional dolutegravir exposure. For women without HIV, the NTD rate was 4·1 per 10 000 live births (95% CI 3·9-4·3) in MarketScan and 5·7 per 10 000 live births (5·6-5·8) in Medicaid. No NTD cases were found among those with dolutegravir or non- dolutegravir antiretroviral drug exposure in the MarketScan data; only one NTD case was identified among women with dolutegravir, and three among women with non-dolutegravir antiretroviral exposure in Medicaid. After adjusting for covariates, there were no significant differences in risk ratios of NTD between groups with periconceptional dolutegravir or non-dolutegravir antiretroviral exposure and the group without HIV. However, compared with women without HIV, the risk of pregnancy loss was higher among women exposed to antiretroviral therapy: for dolutegravir exposure the adjusted risk ratio was 1·73 (95% CI 1·20-2·49) in MarketScan data and 1·41 (1·30-1·54) in Medicaid data; for non-dolutegravir antiretroviral exposure the adjusted risk ratio was 1·23 (1·10-1·37) in MarketScan data and 1·11 (1·07-1·15) in Medicaid data.
    Interpretation: We studied the largest US cohort of women with periconceptional or early-pregnancy dolutegravir exposure. Our results do not show an increased risk of NTDs in exposed infants in the USA. Administrative databases can be used, with rigorous methodology, to study correlates of rare outcomes, such as NTDs, and to monitor for adverse pregnancy outcomes in women who receive antiretrovirals.
    Funding: US Centers for Disease Control and Prevention.
    MeSH term(s) Aged ; Pregnancy ; Infant ; Female ; United States/epidemiology ; Humans ; Pregnancy Outcome ; Cohort Studies ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Medicare ; Neural Tube Defects/chemically induced ; Neural Tube Defects/epidemiology ; Abortion, Spontaneous ; Anti-Retroviral Agents/therapeutic use
    Chemical Substances Anti-Retroviral Agents
    Language English
    Publishing date 2023-07-25
    Publishing country Netherlands
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(23)00108-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Trends in the Number and Characteristics of HIV Pre-Exposure Prophylaxis Providers in the United States, 2014-2019.

    Zhu, Weiming / Huang, Ya-Lin A / Kourtis, Athena P / Hoover, Karen W

    Journal of acquired immune deficiency syndromes (1999)

    2021  Volume 88, Issue 3, Page(s) 282–289

    Abstract: Background: The number and characteristics of pre-exposure prophylaxis (PrEP) health care providers in the United States have not been reported.: Methods: We analyzed a national pharmacy database that included >90% of all prescriptions dispensed by ... ...

    Abstract Background: The number and characteristics of pre-exposure prophylaxis (PrEP) health care providers in the United States have not been reported.
    Methods: We analyzed a national pharmacy database that included >90% of all prescriptions dispensed by retail pharmacies and 60%-86% dispensed by mail-order outlets. We estimated the number of PrEP providers by year, provider type, physician specialty, and geographic location. We also measured the Gini coefficients for the distribution of PrEP patients among providers.
    Results: The number of PrEP providers increased from 9621 in 2014 to 65,822 in 2019. In 2019, 68.1% of PrEP providers were physicians. The proportion of nurse practitioners or physician assistants increased from 18.0% in 2014 to 29.7% in 2019. Among all the US health care providers, those who prescribed PrEP increased from 0.7% in 2014 to 4.3% in 2019. Among all general practice/family medicine physicians, the percentage of who prescribed PrEP increased from 1.8% in 2014 to 13.6% in 2019 and from 14.2% to 34.2% among infectious disease physicians. The ratio of PrEP providers to 100 persons with PrEP indications was lowest in the South with 4.4. The Gini coefficient for the distribution of PrEP patients among providers was 0.75 in 2019, with 50% of the PrEP patients prescribed PrEP by 2.2% of PrEP providers.
    Conclusions: An increasing number of providers prescribed PrEP during 2014-2019. The South had the largest number of new HIV diagnoses and greatest need for HIV prevention but had less PrEP service capacity compared with other regions. Expanded access to PrEP services is needed in the United States.
    MeSH term(s) Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/therapeutic use ; Delivery of Health Care ; HIV Infections/drug therapy ; HIV Infections/prevention & control ; Health Knowledge, Attitudes, Practice ; Health Personnel/statistics & numerical data ; Humans ; Pre-Exposure Prophylaxis/methods ; United States
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2021-10-13
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 645053-2
    ISSN 1944-7884 ; 1077-9450 ; 0897-5965 ; 0894-9255 ; 1525-4135
    ISSN (online) 1944-7884 ; 1077-9450
    ISSN 0897-5965 ; 0894-9255 ; 1525-4135
    DOI 10.1097/QAI.0000000000002774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Crush: A Randomized Trial to Evaluate the Impact of a Mobile Health App on Adolescent Sexual Health.

    Martínez-García, Genevieve / Ewing, Alexander C / Olugbade, Yewande / DiClemente, Ralph J / Kourtis, Athena P

    The Journal of adolescent health : official publication of the Society for Adolescent Medicine

    2022  Volume 72, Issue 2, Page(s) 287–294

    Abstract: Purpose: Mobile technology allows delivery of sexual and reproductive health (SRH) information directly to youth. We tested the efficacy of Crush, a mobile application aimed at improving sexual health by promoting the use of SRH services and ... ...

    Abstract Purpose: Mobile technology allows delivery of sexual and reproductive health (SRH) information directly to youth. We tested the efficacy of Crush, a mobile application aimed at improving sexual health by promoting the use of SRH services and contraception among female adolescents.
    Methods: We recruited 1,210 women aged 14-18 years through social media advertising and randomized them into a Crush intervention group and a control group that received a wellness app. At 3 and 6 months post randomization, we compared changes from baseline in behaviors, attitudes, self-efficacy, perceived social norms, birth control knowledge, perceived control and use intentions, and SRH service utilization. Odds ratios were estimated with multivariable logistic regression and adjusted for baseline outcome, age, race/ethnicity, mother's education, and sexual experience.
    Results: There was no difference in accessing SRH services according to study group. Three months post baseline, Crush users had higher odds (p < .05) than control participants of reporting confidence in accessing SRH services (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI]: 1.1-2.3) and of believing that it is a good thing to use birth control consistently (aOR = 2.3, 95% CI: 1.4-3.8). Six months after baseline, Crush users had higher odds than control participants of reporting they can control whether birth control is used every time they have sex (aOR = 1.8, 95% CI: 1.2-2.6) and perceiving they would get pregnant if they did not use birth control (aOR: 1.5, 95% CI: 1.1-2.2). Impacts on other behavioral constructs were also found.
    Discussion: Crush was associated with improvements in knowledge, attitudes, and self-efficacy related to key SRH behaviors and may be a strategy to deliver SRH education to adolescent women. Studies including larger numbers of sexually active adolescents are needed to demonstrate behavioral impacts.
    MeSH term(s) Pregnancy ; Adolescent ; Humans ; Female ; Sexual Health ; Mobile Applications ; Sexual Behavior ; Contraception ; Sex Education ; Reproductive Health/education
    Language English
    Publishing date 2022-11-21
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1063374-1
    ISSN 1879-1972 ; 1054-139X
    ISSN (online) 1879-1972
    ISSN 1054-139X
    DOI 10.1016/j.jadohealth.2022.09.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Identification of pregnancies and their outcomes in healthcare claims data, 2008-2019: An algorithm.

    Ailes, Elizabeth C / Zhu, Weiming / Clark, Elizabeth A / Huang, Ya-Lin A / Lampe, Margaret A / Kourtis, Athena P / Reefhuis, Jennita / Hoover, Karen W

    PloS one

    2023  Volume 18, Issue 4, Page(s) e0284893

    Abstract: Pregnancy is a condition of broad interest across many medical and health services research domains, but one not easily identified in healthcare claims data. Our objective was to establish an algorithm to identify pregnant women and their pregnancies in ... ...

    Abstract Pregnancy is a condition of broad interest across many medical and health services research domains, but one not easily identified in healthcare claims data. Our objective was to establish an algorithm to identify pregnant women and their pregnancies in claims data. We identified pregnancy-related diagnosis, procedure, and diagnosis-related group codes, accounting for the transition to International Statistical Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis and procedure codes, in health encounter reporting on 10/1/2015. We selected women in Merative MarketScan commercial databases aged 15-49 years with pregnancy-related claims, and their infants, during 2008-2019. Pregnancies, pregnancy outcomes, and gestational ages were assigned using the constellation of service dates, code types, pregnancy outcomes, and linkage to infant records. We describe pregnancy outcomes and gestational ages, as well as maternal age, census region, and health plan type. In a sensitivity analysis, we compared our algorithm-assigned date of last menstrual period (LMP) to fertility procedure-based LMP (date of procedure + 14 days) among women with embryo transfer or insemination procedures. Among 5,812,699 identified pregnancies, most (77.9%) were livebirths, followed by spontaneous abortions (16.2%); 3,274,353 (72.2%) livebirths could be linked to infants. Most pregnancies were among women 25-34 years (59.1%), living in the South (39.1%) and Midwest (22.4%), with large employer-sponsored insurance (52.0%). Outcome distributions were similar across ICD-9 and ICD-10 eras, with some variation in gestational age distribution observed. Sensitivity analyses supported our algorithm's framework; algorithm- and fertility procedure-derived LMP estimates were within a week of each other (mean difference: -4 days [IQR: -13 to 6 days]; n = 107,870). We have developed an algorithm to identify pregnancies, their gestational age, and outcomes, across ICD-9 and ICD-10 eras using administrative data. This algorithm may be useful to reproductive health researchers investigating a broad range of pregnancy and infant outcomes.
    MeSH term(s) Infant ; Pregnancy ; Humans ; Female ; Pregnancy Outcome ; Abortion, Spontaneous ; Maternal Age ; Algorithms ; International Classification of Diseases ; Delivery of Health Care
    Language English
    Publishing date 2023-04-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0284893
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: An estimate of excess deaths among people with HIV during the coronavirus disease 2019 pandemic in the United States, 2020.

    Zhu, Weiming / Huang, Ya-Lin A / Song, Ruiguang / Wiener, Jeffrey / Neblett-Fanfair, Robyn N / Kourtis, Athena P / Hoover, Karen W

    AIDS (London, England)

    2023  Volume 37, Issue 5, Page(s) 851–853

    Abstract: We developed an ad hoc method to estimate the number of excess deaths among persons with HIV (PWH) during the coronavirus disease 2019 (COVID-19) pandemic in the United States. Using this method, we estimated approximately 1448 excess deaths from COVID- ... ...

    Abstract We developed an ad hoc method to estimate the number of excess deaths among persons with HIV (PWH) during the coronavirus disease 2019 (COVID-19) pandemic in the United States. Using this method, we estimated approximately 1448 excess deaths from COVID-19 among PWH in 2020 in the United States. We also developed an Excel workbook for use as a tool to quickly assess excess deaths among PWH in settings with limited surveillance data.
    MeSH term(s) Humans ; United States/epidemiology ; COVID-19 ; Pandemics ; HIV Infections/complications
    Language English
    Publishing date 2023-02-07
    Publishing country England
    Document type Letter
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0000000000003503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top